Parkinson's disease (PD) is the second most common progressive neurodegenerative disorder, which results directly from the relatively selective loss of nigrostriatal dopaminergic neurons. PD is a heterogeneous disorder of unclear etiology, and although the majority of cases appear sporadic in nature, specific genetic defects have recently been identified in rare familial cases of PD. To date, mutations in three genes are linked to familial PD, alpha-synuclein, parkin, and more recently DJ-1. Mutations in the DJ-1 gene are linked with autosomal recessive early-onset PD in two consanguineous European families. In one affected Dutch family, a 14 kb homozygous genomic deletion within the DJ-1 gene appears to abolish DJ-1 expression. In an Italian family, a homozygous missense mutation, L166P, of the DJ-1 protein is the disease causing entity. This L 166P mutant may result in mislocalization of DJ-1 to mitochondria and may promote loss of protein stability. Disruptions of the DJ-1 gene may result in familial PD, however, the mechanisms by which loss of normal DJ-1 function triggers disease are not known. In fact the normal function of DJ-1 is not yet known. To explore the biologic role of DJ- 1 and understand the actions of the disease causing mutations the following specific aims are proposed:
Aim 1 : Do DJ- 1 mutants affect the structure and function of DJ- 1? Aim 2: Does DJ-1 bind or interact with other proteins implicated in the pathogenesis of PD? Aim 3: What is the effect of loss of function or overexpression of DJ- 1 on cell viability? Aim 4: What is the expression pattern of DJ-1 in normal and Parkinson's disease tissue? Aim 5: Identification of proteins that interact with DJ-1. On conclusion of this project we hope to better understand the biologic role of DJ-1, the consequences of loss of DJ-1 activity and an understanding of how or if DJ- 1 interact with other signaling pathways already associated with PD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS038377-09
Application #
7491152
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
9
Fiscal Year
2007
Total Cost
$387,056
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Berger, Nathan A; Besson, Valerie C; Boulares, A Hamid et al. (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 175:192-222
Wu, Xinyan; Zahari, Muhammad Saddiq; Renuse, Santosh et al. (2018) Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts. Clin Proteomics 15:21
Blauwendraat, Cornelis; Pletnikova, Olga; Geiger, Joshua T et al. (2018) Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiol Aging :
Heo, Seok; Diering, Graham H; Na, Chan Hyun et al. (2018) Identification of long-lived synaptic proteins by proteomic analysis of synaptosome protein turnover. Proc Natl Acad Sci U S A 115:E3827-E3836
Dawson, Ted M; Golde, Todd E; Lagier-Tourenne, Clotilde (2018) Animal models of neurodegenerative diseases. Nat Neurosci 21:1370-1379
Lee, Saebom; Kim, Sangjune; Park, Yong Joo et al. (2018) The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model. Hum Mol Genet 27:2344-2356
Xiong, Yulan; Neifert, Stewart; Karuppagounder, Senthilkumar S et al. (2018) Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proc Natl Acad Sci U S A 115:1635-1640
Yun, Seung Pil; Kam, Tae-In; Panicker, Nikhil et al. (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med 24:931-938
Hinkle, Jared Thomas; Perepezko, Kate; Bakker, Catherine C et al. (2018) Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. Mov Disord Clin Pract 5:31-38
Kam, Tae-In; Mao, Xiaobo; Park, Hyejin et al. (2018) Poly(ADP-ribose) drives pathologic ?-synuclein neurodegeneration in Parkinson's disease. Science 362:

Showing the most recent 10 out of 250 publications